PROfound Puts Lynparza On Track For Prostate Cancer Indication

 
• By Sten Stovall
  
Cancer_Cell
Lynparza could become the first PARP inhibitor in prostate cancer. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D